Allurion Technologies

ALUR · NYSE

$0.475−$0.46 (−49.20%)TodayMarket closed · Oct 20, 2:36 PM ET

No price history for this range.

ALUR analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 3 analysts

Average $122.40 (+25668.4% upside)

Low: $121.20
Now: $0.475
High: $126.00

Upgrades and downgrades

The latest rating actions, newest first

ALUR analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Chardan Capital	Feb 24, 2026	Upgrade	Neutral → Buy	$2.50 → $3.00	38%
Chardan Capital	Nov 20, 2025	Maintains	Neutral	$2.50	38%

The case for and against

Updated May 12, 2026

Bull case

Allurion Technologies is a promising medical device company with a unique and innovative weight loss platform that could potentially disrupt the traditional weight loss industry. The company has a strong global presence with its CE Mark approval, and is moving closer to FDA approval for its Allurion Smart Capsule, which could significantly increase its market potential. The company's financials show a history of losses, but this is not uncommon for early-stage medical device companies. However, the potential for lack of reimbursement and adverse changes in the economy could pose challenges for the company's growth and profitability. To mitigate these risks, Allurion will have to successfully manage clinical trials and raise necessary funds for further development and commercialization efforts.

Bear case

Allurion Technologies is heavily reliant on self-pay patients as its weight loss treatments are not typically covered by insurance, putting a strain on their financial performance. The company must also navigate the complex landscape of regulatory approvals and clinical trials for their innovative medical device, which can be time-consuming and costly. Additionally, competition from larger companies may affect their market share and revenue. These risks, combined with limited international sales experience and reliance on third-party distributors, may contribute to a negative outlook for the company's stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.